# To Evaluate the Efficacy of CT041 in Sequential Treatment After First-line Treatment of Advanced Gastric/Esophagogastric Junction Adenocarcinoma

> **NCT07179484** · — · RECRUITING · sponsor: **Beijing GoBroad Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** CT041 autologous CAR T-cell injection

## Key facts

- **NCT ID:** NCT07179484
- **Lead sponsor:** Beijing GoBroad Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-22
- **Primary completion:** 2027-09-01
- **Final completion:** 2028-09-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07179484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07179484, "To Evaluate the Efficacy of CT041 in Sequential Treatment After First-line Treatment of Advanced Gastric/Esophagogastric Junction Adenocarcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07179484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*